drugset / Trial / NCT05309915
A Study of STP707 Administered by IV in Healthy Subjects
RandomizedSequentialOpen-labelTreatment
Summary
Single center study, randomized, to evaluate safety, tolerability, PK of single ascending dose of STP707 when administered by IV infusion in healthy subjects.
Timeline
- Start
- 2022-02-28
- Primary completion
- 2022-08-30
- Completion
- 2022-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | STP707 | Small interfering RNA (siRNA) | 3 mg | Intravenous |
| Subject | STP707 | Small interfering RNA (siRNA) | 6 mg | Intravenous |
| Subject | STP707 | Small interfering RNA (siRNA) | 12 mg | Intravenous |
| Subject | STP707 | Small interfering RNA (siRNA) | 24 mg | Intravenous |
Indications
No indication recorded.